🧬The Technological Renaissance in Reproductive Medicine: Artificial Intelligence and the Transformation of Severe Male Infertility Treatment

The landscape of reproductive healthcare in 2026 is undergoing a paradigm shift, characterized by the convergence of high-performance computing, micro-robotics, and advanced biotechnology. Male infertility, long the "silent" contributor to approximately half of all global infertility cases, has reached a critical focal point within clinical and economic agendas.[1] Historically, the treatment of severe male-factor infertility—particularly non-obstructive azoospermia (NOA)—has been hindered by the limitations of human visual perception and the manual complexity of laboratory procedures. However, the emergence of "Repro-AI" has introduced autonomous systems capable of identifying and isolating viable sperm cells in samples previously classified as sterile.[3] This investigation explores the forensic details of these breakthroughs, the underlying machine learning architectures, and the macroeconomic shifts redefining the global fertility market.

The Medical Breakthrough: Navigating the Search for Hidden Sperm

The fundamental challenge in treating severe male infertility lies in the identification of rare spermatozoa within a vast volume of cellular debris. In patients with non-obstructive azoospermia, sperm production is often focal, occurring in isolated tubules within the testes or appearing in exceedingly low concentrations in the ejaculate.[5] For decades, embryologists spent upwards of 15 hours manually scanning samples under high magnification, a process described by clinicians as searching for a needle in a thousand haystacks.[4]

The STAR Method and the Legacy of Zev Williams

The most profound medical breakthrough of the 2025-2026 period is the Sperm Tracking and Recovery (STAR) method, developed by Dr. Zev Williams and a multidisciplinary team at the Columbia University Fertility Center.[4] The conceptual origin of STAR is rooted in an unlikely field: astrophysics. By adapting algorithms used to identify nascent galaxies in the deep noise of space, the Columbia team created a system capable of discerning the minute structural signatures of sperm cells against the background of testicular tissue fragments and red blood cells.[7]

The STAR system utilizes a high-powered imaging platform connected to a specialized microfluidic chip. In a clinical demonstration that fundamentally altered the prognosis for azoospermic patients, the AI scanned a 3.5 mL semen sample and processed over 8 million images in less than an hour.[4] While human technicians had previously searched the same sample for two days without success, the STAR AI identified 44 viable sperm cells in approximately 60 minutes.[4] This capability enabled the first successful pregnancy for a couple who had struggled with infertility for 18 years, having failed multiple conventional in vitro fertilization (IVF) cycles and two prior surgical sperm extractions.[4]

T'easy and the Optimization of Testicular Biopsies

Parallel to the developments in North America, the Brussels IVF center at UZ Brussel introduced

"T'easy," an AI-powered diagnostic platform focused specifically on testicular biopsy samples.[6] Testicular Sperm Extraction (TESE) is the surgical retrieval of tissue from the testes to find sperm for use in intra-cytoplasmic sperm injection (ICSI). The manual detection of sperm in these samples is exceptionally labor-intensive. T'easy employs an integrated app and a modified microscope to automate this detection process, achieving a recall rate of 95% and a precision of 94.8% in initial testing.[6]

Performance Metric	**Manual Embryologist**	**T'easy AI System**
Average Search Time (Biopsy)	24 - 120 Minutes	10 Minutes
Recall (Identification Accuracy)	Highly Variable	95%
Precision (True Positive Rate)	Subjective	94.8%
Detection Probability	Focal-dependent	98% of present cells
Patient Anesthesia Duration	Extended	Significantly Reduced

.[6]

The introduction of T'easy represents more than a speed enhancement; it is a clinical safety improvement. By reducing the time required to confirm the presence of sperm, the system minimizes the duration patients spend under general anesthesia, thereby reducing the risk of surgical complications and accelerating post-operative recovery.[10]

Machine Learning Architectures: The Core of Sperm Identification

The success of systems like STAR, T'easy, and SpermSearchAI depends on the evolution of computer vision, specifically the ability of deep learning models to process high-resolution video streams in real time. Unlike static image analysis, sperm selection requires the assessment of both morphology (shape) and motility (movement).[12]

YOLOv5 and Real-Time Object Detection

The technical backbone for many of these systems is the YOLO (You Only Look Once) architecture, specifically YOLOv5. In experiments conducted on seminiferous tubule sample images, YOLOv5 models have outperformed traditional feature extraction methods like AKAZE or MB-LBP descriptors.[14] Previous methods often suffered from high recall but low precision, leading to "false positives" where cellular debris was incorrectly flagged as sperm. YOLOv5, through its single-pass neural network architecture, achieves a precision of 0.81, allowing for rapid and accurate detection during the surgical window.[14]

The transition to YOLO-based detection allows for the implementation of augmented reality (AR) interfaces. In these setups, the AI highlights sperm cells in real-time on the embryologist's screen, effectively doubling the detection rate from 30.8% to 66.9%.[14] This synergy between human expertise and machine speed ensures that even the most subtle indicators of life are captured.

Predictive Modeling and Morphometric Data

Beyond identification, AI is being used to predict the likelihood of successful sperm retrieval before a single incision is made. Researchers have developed multi-variable models that integrate clinical characteristics with testicular pathological morphometric parameters. The primary predictive equation utilized in 2026 relies on four key variables: the diameter of the seminiferous tubules (DT), the height of the seminiferous epithelium (HSE), the Johnsen score (a histological measure of spermatogenesis), and serum follicle-stimulating hormone (FSH) levels.[15]

The mathematical model is defined as:

$$Score = -0.612 - 0.018 \times DT + 0.040 \times HSE + 0.097 \times \text{Johnsen Score} - 0.004 \times \text{Serum FSH}$$

.[15]

This formula has demonstrated an Area Under the Curve (AUC) of 0.839, with a predictive accuracy of 89.25% in external validation datasets.[15] By quantifying these parameters, clinicians can provide personalized counseling, helping patients understand their realistic chances of success and potentially avoiding unnecessary surgeries for those with scores below the critical cut-off of 0.489.[15]

Biotechnology and the Robotic Interface

The identification of sperm is only the first half of the clinical challenge; the second half is the physical isolation of the cell for use in ICSI. This has led to the rise of autonomous robotic platforms that integrate computer vision with micro-manipulation technology.[10]

The BAIBYS Autonomous Platform

BAIBYS, a prominent technology firm in the 2026 landscape, has developed a "fully autonomous" system that manages the sperm selection workflow from end to end.[13] The platform utilizes a sub-micrometer motorized X-Y stage and intelligent scanning technology (IST) to track living sperm cells at high magnification.[12] Once the AI classifies a sperm cell as "ideal" based on WHO criteria for morphology and motility, the system autonomously controls a micro-manipulator to pick up and isolate the cell into a separate droplet.[12]

The clinical utility of BAIBYS lies in its ability to standardize a process that was previously highly subjective. In a healthy semen sample, approximately 96% of sperm are structurally abnormal; identifying the elite 4% requires extreme concentration and skill.[18] By automating this, BAIBYS reduces the dependency on specialized lab personnel and ensures that the "best" sperm—those most likely to produce a usable blastocyst—are selected every time.[17]

Feature	**Conventional Manual ICSI**	**BAIBYS Autonomous ICSI**
Selection Criteria	Subjective visual assessment	Standardized AI classification
Procedure Time	1 - 3 Hours	Minutes
Magnification Level	200x - 400x	High-magnification (up to 6000x)
Isolation Method	Manual Pipetting	Robotic micro-manipulation
Dependence on Skill	High (Embryologist fatigue)	Low (Autonomous consistency)

.[12]

Unstained Live Sperm Assessment

A significant biotechnological hurdle in male fertility has been the inability to assess internal sperm structure without killing the cell. Traditional morphology assessment requires staining, which is lethal to spermatozoa.[19] AI models in 2026 have solved this by analyzing "unstained" live sperm through phase-contrast imaging and refractive index variations. These models can recognize subtle internal abnormalities—such as vacuole presence or chromatin decondensation—in living cells, allowing for immediate selection and fertilization.[19]

Human Clinical Impact: Redefining "Sterility"

The integration of AI into infertility treatment is fundamentally changing the patient experience, shifting the narrative from one of despair to one of managed clinical outcomes. The ability to identify "hidden" sperm has effectively moved the definition of sterility, as patients previously told they had zero chance of biological fatherhood are now achieving successful pregnancies.[4]

Case Studies in Prolonged Infertility

The psychological and emotional toll of infertility is documented as being equally severe for both men and women.[22] The 18-year journey of the first couple treated with the STAR method highlights the resilience required for modern fertility treatment. After two decades of disappointments, the discovery of just two viable sperm cells led to a healthy pregnancy, an outcome that underscores the high stakes of precision diagnostics.[4]

In another study conducted by Virtus Health, SpermSearchAI reduced sperm search times by up to 75%, which allowed clinics to treat more complex cases without increasing laboratory wait times.[24] This speed is not merely an operational metric; for the patient, it represents a reduction in the time spent in the "liminal space" between diagnosis and result. Furthermore, first-time Micro-TESE cases have shown success rates as high as 64.6%, compared to only 28.8% for repeated procedures, suggesting that the early application of AI-assisted retrieval is critical for maximizing outcomes.[25]

Embryo Selection and the Path to Live Birth

The male factor is only one part of the equation; once fertilization occurs, AI continues to play a role in embryo assessment. Systems like Alife's Embryo Predict™ and the PRIDE study's iDAScore utilize deep learning to rank embryos based on their implantation potential.[10]
AI-assisted embryo selection has demonstrated a significant increase in the accuracy of live birth predictions, enabling the transition to single embryo transfer (SET).[28] This reduces the incidence of multiple pregnancies, which are historically high-risk for both the mother and the infants.[28]

Clinical Milestone	Impact of AI Integration

Diagnostic Accuracy	Precision > 94% in identifying rare sperm
Patient Experience	75% reduction in search-related delays
Surgical Safety	50% - 60% reduction in time under anesthesia
Live Birth Potential	Improved via standardized embryo ranking
Treatment Success	63% success rate in previously "sterile" men

.[4]

Macroeconomics of the Global Fertility Market

The global fertility industry is a multi-billion dollar sector that is currently experiencing a period of accelerated growth, driven by delaying childbearing, rising awareness of male-factor issues, and the adoption of high-tech interventions.[1] By 2026, the global infertility treatment market is estimated to reach approximately $37.1 billion, with the male infertility segment alone valued at $4.8 billion to $5.1 billion.[2]

Market Dynamics and Growth Drivers

The annual growth rate of the IVF industry is approximately 10%, with a projected increase from $638 million in 2021 to nearly $1 billion by 2026 for AI-specific software and instrument subsets.[3] Several macroeconomic factors contribute to this expansion:

1. Increasing Paternal Age: The average age of first-time fathers has risen significantly (e.g., to 33.8 in Quebec from 30.3 in the 1970s), leading to a higher prevalence of sperm DNA fragmentation and other age-related issues.[2]
2. The Global Sperm Crisis: Research indicating a 50% decline in sperm counts over the last five decades has spurred investment in "Repro-AI" as a necessary adaptation to a biological trend.[13]
3. Societal Shift: Increased public awareness and the destigmatization of male infertility have led to a surge in demand for diagnostic tests, such as DNA fragmentation analysis, which currently holds a 21.77% market share.[2]

The Economics of AI Adoption

While the initial cost of implementing AI systems like STAR or BAIBYS is high, the long-term economic argument is one of efficiency and cost-reduction. A single round of IVF costs an average of $23,474, and many couples require three or more rounds.[3] By increasing the probability of success in the first cycle, AI-driven treatments can save patients tens of thousands of dollars in the long run.[3]

Market Metric	2025 Value (USD)	2026 Projection (USD)	2035 Projection (USD)
Global Male Infertility Market	$4.42 - $4.59 B	$4.80 - $5.10 B	$7.55 - $8.33 B
Global Fertility Treatment Market	$34.63 B	$37.10 B	$52.33 B (by 2031)
AI in IVF Specific Segment	$638 M (2021)	$987 M	-
DNA Fragmentation Market Share	21.77%	-	-

.[1]

The introduction of the TrumpRx initiative in 2025-2026, which aims to lower drug prices and encourage employers to offer fertility benefits through Health Reimbursement Arrangements (HRAs), is expected to further democratize access to these high-tech treatments.[33] Clinics that adopt AI are positioning themselves as high-efficiency hubs that can process more patients with fewer staff members, mitigating the global shortage of trained embryologists.[10]

Regulatory Hurdles and the Evolving Legal Landscape

The transition of AI from a research curiosity to a regulated medical device has required the development of entirely new oversight frameworks. In 2025 and 2026, regulatory bodies like the

FDA and the EMA have moved toward a "Total Product Life Cycle" (TPLC) approach, acknowledging that AI systems are dynamic and evolve over time.[34]

The FDA's Risk-Based Credibility Assessment

In January 2025, the FDA issued landmark guidance on AI-enabled device software, which categorizes systems into three distinct tiers based on their level of clinical autonomy.[35]

FDA Risk Tier	System Functionality	Regulatory Requirements
Tier 1: Informing	AI suggests, clinician decides (e.g., image annotation)	Transparency labeling, bias documentation
Tier 2: Driving	AI initiates workflow with limited override (e.g., diagnostics)	Full PCCP engineering, RWE monitoring
Tier 3: Treating	AI autonomously actuates decisions (e.g., robotic surgery)	Non-negotiable bias controls, SPDF/SBOM obligations

.[35]

A critical component of this new framework is the Predetermined Change Control Plan (PCCP). This allows companies like Alife or BAIBYS to pre-authorize future updates to their algorithms, provided they can demonstrate a rigorous validation protocol.[35] This shift is essential for the fast-paced world of machine learning, where waiting months for a new 510(k) approval for every minor model optimization would stifle innovation.

Global Harmonization and Data Privacy

As fertility care becomes increasingly digital, the protection of sensitive genetic and reproductive data has become a national security priority. Audits conducted in 2025 revealed vulnerabilities in how research data was shared internationally, leading to stricter access controls for genomic databases.[36] Furthermore, the transition to the EU Medical Device Regulation (MDR) has set a new global benchmark for transparency. Alife's Embryo Predict™ received its CE mark in late 2025, representing the first time an AI platform met the stringent requirements of the MDR, which includes mandatory reporting on model architecture and dataset representativeness.[10]

Biological Data: The Ethics and Training Paradigms

The "black box" nature of AI remains a concern in reproductive medicine. To build trust, developers must move toward "explainable AI" (XAI), where the system provides the reasoning for its selections.[22]

Training on Diverse Datasets

The efficacy of a sperm-selection algorithm is only as good as the data it was trained on. Early models often suffered from "overfitting," where they performed well in the lab but failed in real-world clinical environments with different imaging equipment. By 2026, datasets have expanded to include millions of labeled images from diverse global populations.[6]

For instance, the T'easy system was trained using more than 13,000 labeled sperm cells across 5,000 images, meticulously double-annotated by senior staff.[6] This rigor ensures that the AI can handle the "noise" of clinical samples, such as the presence of red blood cells or the varying thickness of testicular tissue samples.

Ethical Considerations and the "Three-Person IVF" Frontier

As AI optimizes the selection of gametes, the field is also grappling with more advanced biological interventions, such as mitochondrial replacement therapy (three-person IVF). While AI helps select the best nuclear material, these mitochondrial techniques address the energetic health of the egg.[10] The intersection of these technologies raises profound questions about the limits of human intervention in reproduction. While AI-guided sperm recovery is largely seen as a restorative medical technology, the potential for using AI to screen for polygenic traits in embryos remains an ethical frontier with significant societal implications.[10]

Synthesis and Future Projections

The revolution in male infertility treatment is not the result of a single discovery but the synergistic integration of four distinct domains: high-speed computer vision (YOLOv5/STAR), micro-robotics (BAIBYS), predictive biometry (NOA scoring), and a favorable macroeconomic environment (Repro-AI market growth).[3]

By 2030, it is projected that autonomous sperm selection will be the standard of care in all major fertility centers. The "needle in the haystack" problem will be viewed as a historical artifact of a manual era. The implications for public health are significant: as sperm counts continue to decline globally, these technologies provide a biological insurance policy, ensuring that the desire for parenthood remains attainable despite shifting environmental and lifestyle pressures.[13]

The macro-trend toward "DIY" or decentralized IVF cycles—supported by home-based hormonal screening and AI-driven counseling—suggests that the next decade will see a further democratization of fertility care.[30] However, the human embryologist will remain at the center of this ecosystem, transitioning from a manual searcher to a high-level data overseer who manages the "Human-in-the-Loop" requirements that define the 2026 regulatory landscape.[28]

The investigative findings confirm that Artificial Intelligence has moved beyond a supportive role and is now the primary engine of innovation in male reproductive health. The success stories of the STAR and T'easy systems are the first in what will likely be a comprehensive transformation of the path to biological fatherhood, offering hope to a population that was, until very recently, told they were out of options.[4]

Works cited

1. Male Infertility Market Size & Share 2026-2032, accessed on May 1, 2026, https://www.360iresearch.com/library/intelligence/male-infertility
2. Male Infertility Market | USD 8.05 Billion by 2035 - Nova One Advisor, accessed on May 1, 2026, https://www.novaoneadvisor.com/report/male-infertility-market
3. How Artificial Intelligence is Redefining Fertility – The Princeton ..., accessed on May 1, 2026, https://medreview.odus.princeton.edu/2025/04/12/how-artificial-intelligence-is-redefining-fertility/
4. STAR Method AI system just achieved its first pregnancy azoospermia - Conceive with Ease, accessed on May 1, 2026, https://conceivewithease.ie/news/star-method-ai-first-pregnancy
5. AI-Guided Sperm Analysis Results In First Successful Pregnancy - Drugs.com MedNews, accessed on May 1, 2026, https://www.drugs.com/news/ai-guided-sperm-analysis-results-first-successful-pregnancy-127418.html
6. UZ Brussel develops AI tool for faster and more efficient detection of sperm cells, accessed on May 1, 2026, https://uz-brussel.prezly.com/uz-brussel-develops-ai-tool-for-faster-and-more-efficient-detection-of-sperm-cells
7. The University Research Behind Eight of TIME's Best Inventions of 2025, accessed on May 1, 2026, https://www.aau.edu/newsroom/leading-research-universities-report/university-research-behind-eight-times-best
8. Columbia University STAR method: The Best Inventions of 2025 - Time Magazine, accessed on May 1, 2026, https://time.com/collections/best-inventions-2025/7318439/columbia-university-star-method/
9. AI-Guided Sperm Recovery Method Brings First Pregnancy Success | Outlook India, accessed on May 1, 2026, https://www.outlookindia.com/healthcare-spotlight/ai-guided-sperm-recovery-method-brings-first-pregnancy-success
10. 2025: The year IVF innovation went from lab to life - FemTech World, accessed on May 1, 2026,

https://www.femtechworld.co.uk/news/fertility-news/2025-the-year-ivf-innovation-went-from-lab-to-life-fbc25/
11. Brussels University Hospital: Driving Innovation in Patient-Centered Research and Care, accessed on May 1, 2026, https://belgian-research.eu/brussels-university-hospital-driving-innovation-in-patient-centered-research-and-care/
12. Technology - BAIBYS™ Fertility, accessed on May 1, 2026, https://www.baibys.com/technology/
13. BAIBYS TM Autonomous Sperm Selection System for IVF Receives CE Mark, accessed on May 1, 2026, https://www.baibys.com/news-and-events/news/baibys-autonomous-sperm-selection-system-for-ivf-receives-ce-mark/
14. AI-Based Augmented Reality Microscope for Real-Time Sperm ..., accessed on May 1, 2026, https://www.mdpi.com/2306-5354/13/1/102
15. Development of a predictive model and nomogram in sperm retrieval rate based on testicular pathological morphometric parameters in non-obstructive azoospermia patients: a multi-center study - PMC, accessed on May 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12771997/
16. International news in brief: IVF pregnancy achieved with “fully autonomous” system, Prince Edward Island AVT pilot, Amazon weight management programme, accessed on May 1, 2026, https://htn.co.uk/2026/04/29/international-news-in-brief-ivf-pregnancy-achieved-with-fully-autonomous-system-prince-edward-island-avt-pilot-amazon-weight-management-programme/
17. Evaluating the Safety and Clinical Efficacy of the BAIBYS™ System in Intracytoplasmic Sperm Injection (ICSI) | MedPath, accessed on May 1, 2026, https://trial.medpath.com/clinical-trial/1a6dcfc7e5fbfa00/nct06990906-benchmark-sperm-baibys-system-icsi
18. State of Devices and Consumables: 2026 — Fertility Bridge, accessed on May 1, 2026, https://www.fertilitybridge.com/news-articles/ivf-devices-standardization-2026
19. Top Fertility Tests for Men in 2026 | AI & Semen Analysis, accessed on May 1, 2026, https://www.andrologycenter.in/blog/top-fertility-tests-for-men-in-2026-integrating-ai-with-semen-analysis/
20. Artificial Intelligence and Male Infertility - Frontiers, accessed on May 1, 2026, https://www.frontiersin.org/research-topics/64362/artificial-intelligence-and-male-infertility
21. Micro-TESE: A 2026 Breakthrough for Men with Zero Sperm Count - Dr Jayesh Amin, accessed on May 1, 2026, https://drjayeshaminivf.com/micro-tese-breakthrough-azoospermia-2026/
22. ESHRE 2025 Abstract Highlights - European Medical Journal - EMJ, accessed on May 1, 2026, https://www.emjreviews.com/reproductive-health/abstract/eshre-2025-abstract-highlights-j150125/

23. A couple tried for 18 years to get pregnant. AI made it happen - WRAL, accessed on May 1, 2026, https://www.wral.com/story/a-couple-tried-for-18-years-to-get-pregnant-ai-made-it-happen/22073663/
24. Dale Goss Presents Groundbreaking AI Sperm Selection Study | IVF & Fertility Blog Australia, accessed on May 1, 2026, https://www.ivf.com.au/blog/dale-goss-presents-groundbreaking-ai-sperm-selection-study
25. Predictors of sperm retrieval success in first-time and repeated Micro ..., accessed on May 1, 2026, https://www.tandfonline.com/doi/full/10.1080/20565623.2025.2511449
26. Study Details | NCT07187934 | EVALUATION OF A FULLY AUTOMATED AI TOOL FOR EMBRYO RANKING | ClinicalTrials.gov, accessed on May 1, 2026, https://clinicaltrials.gov/study/NCT07187934
27. Fertility tech in 2023: At-home, personalisation and accessibility - Medical Device Network, accessed on May 1, 2026, https://www.medicaldevice-network.com/features/fertility-tech-in-2023-at-home-personalisation-and-accessibility/
28. AI in Embryo Selection: Improving IVF Success Rates in 2026, accessed on May 1, 2026, https://zemyaivf.com/ai-in-embryo-selection-improving-ivf-success-rates-in-2026/
29. IVF Instruments Market Size, Share | Industry Report [2033], accessed on May 1, 2026, https://www.skyquestt.com/report/ivf-instruments-market
30. Will Artificial Intelligence Change the Future of IVF? - PMC, accessed on May 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9666597/
31. Male Infertility Market Size, Share, Trends & Growth Analysis 2035 - Research Nester, accessed on May 1, 2026, https://www.researchnester.com/reports/male-infertility-market/6485
32. Fertility Treatment Market Size, Trends, Share & Research Report 2031 - Mordor Intelligence, accessed on May 1, 2026, https://www.mordorintelligence.com/industry-reports/global-fertility-treatment-market
33. Evaluating the Trump Administration's Initiative on IVF | American Society for Reproductive Medicine, accessed on May 1, 2026, https://www.asrm.org/advocacy-and-policy/fact-sheets-and-one-pagers/evaluating-the-trump-administrations-initiative-on-ivf/
34. AI IP Year in Review - Regulatory Update: FDA Issues Draft Guidances for AI Use in Medical Devices and for Drugs and Biologics | Sterne Kessler, accessed on May 1, 2026, https://www.sternekessler.com/news-insights/insights/ai-ip-year-in-review-regulatory-update-fda-issues-draft-guidances-for-ai-use-in-medical-devices-and-for-drugs-and-biologics-2/
35. FDA's AI Device Guidelines Evolve: How Medtech Can Adapt, accessed on May 1, 2026, https://www.mddionline.com/artificial-intelligence/fda-s-ai-device-regulations-key-u

pdates-compliance-strategies-for-medtech-success
36. ADLM supports FDA effort to develop regulations for AI medical devices | myadlm.org, accessed on May 1, 2026, https://myadlm.org/cln/articles/2026/januaryfebruary/adlm-supports-fda-effort-to-develop-regulations-for-ai-medical-devices
37. AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information - Federal Register, accessed on May 1, 2026, https://www.federalregister.gov/documents/2026/04/29/2026-08281/ai-enabled-optimization-of-early-phase-clinical-trials-pilot-program-request-for-information
38. AI and Infertility Treatment - How Will AI Be Involved? - Center Human Reproduction, accessed on May 1, 2026, https://centerforhumanreprod.com/reproductive-health-blog/ai-and-infertility-treatment-how-will-ai-be-involved